Skip to main content

Unity Biotechnology, Inc.

UBXDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001463361

Unity Biotechnology, Inc. was delisted in 2025; its insiders filed their last Form 4 on Apr 3, 2025; 35 institutions reported holding it in 13F filings for Q2 2025, worth $987.3K in total; no superinvestor held it.

Key figures

Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
35
Q2 2025, −5 vs. previous quarter
13F value
$987.3K
Reported value at the end of Q2 2025
Superinvestors holding
0
At the end of Q2 2025

Superinvestors holding UBX, Q2 2025

Go to the superinvestors tab

No superinvestor reported holding UBX at the end of Q2 2025.

Latest insider trades

Open-market purchases and sales by Unity Biotechnology, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 3, 2025 (view filing)Apr 21 dayNguyen Alexander HieuCLO and Head of OpsSSaleCommon Stock, $0.0001 par value−17.9K$1.03−$18.4K−26.8%48.8K after
Apr 3, 2025 (view filing)Apr 21 daySullivan Lynne MarieCFO & Head of Corp. Dev.SSaleCommon Stock, $0.0001 par value−21.9K$1.03−$22.5K−18.1%98.9K after
Apr 3, 2025 (view filing)Apr 21 dayGhosh AnirvanChief Executive OfficerSSaleCommon Stock, $0.0001 par value−96.8K$1.03−$99.7K−38.7%153.5K after
Mar 31, 2025 (view filing)Mar 274 daysNguyen Alexander HieuCLO and Head of OpsSSaleCommon Stock, $0.0001 par value−1.95K$1.16−$2.27K−8.0%22.6K after
Feb 5, 2025 (view filing)Feb 41 daySullivan Lynne MarieCFO & Head of Corp. Dev.SSaleCommon Stock, $0.0001 par value−153$2.23−$341.19−0.3%55.8K after
Feb 5, 2025 (view filing)Feb 41 dayNguyen Alexander HieuCLO and Head of OpsSSaleCommon Stock, $0.0001 par value−164$2.23−$365.72−0.7%24.6K after
Feb 5, 2025 (view filing)Feb 41 dayGhosh AnirvanChief Executive OfficerSSaleCommon Stock, $0.0001 par value−642$2.23−$1.43K−0.8%75.3K after
Nov 6, 2024 (view filing)Nov 42 daysSullivan Lynne MarieCFO & Head of Corp. Dev.SSaleCommon Stock, $0.0001 par value−136$1.29−$175.44−0.2%55.9K after
Nov 6, 2024 (view filing)Nov 42 daysNguyen Alexander HieuChief Legal OfficerSSaleCommon Stock, $0.0001 par value−149$1.29−$192.21−0.6%24.7K after
Nov 6, 2024 (view filing)Nov 42 daysGhosh AnirvanChief Executive OfficerSSaleCommon Stock, $0.0001 par value−432$1.29−$557.28−0.6%75.9K after

Top 10 13F holders, Q2 2025

The largest institutional positions in Unity Biotechnology, Inc. at the end of Q2 2025; share changes are against Q1 2025.

See all 35 holders
Institutions holding UBX in Q2 2025
InstitutionSharesValue% of portfolioChange in sharesAction
ARCH Venture Management, LLC1,004,817$385.9K0.13%00.0%Unchanged
Vanguard Group Inc673,090$255.8K0.00%00.0%Unchanged
Geode Capital Management, LLC169,025$64.2K0.00%+2,812+1.7%Added
UBS Group AG152,327$58.5K0.00%+128,026+526.8%Added
Renaissance Technologies LLC98,311$37.8K0.00%+4,100+4.4%Added
BlackRock, Inc.81,402$31.3K0.00%00.0%Unchanged
Morgan Stanley60,556$23.3K0.00%+17,200+39.7%Added
Susquehanna International Group, LLP56,720$21.6K0.00%−6,016−9.6%Reduced
Founders Fund V Management, LLC49,172$18.7K1.36%00.0%Unchanged
State Street Corp37,824$14.4K0.00%00.0%Unchanged